Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT01818661
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Apraxia of Speech
  • Non-fluent Aphasia
  • PPA
  • Primary Progressive Aphasia
  • Primary Progressive Non-fluent Aphasia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AV-1451 — DRUG
    This is used to assess Tau burden in the brain.

Study Details

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).

Key Dates

Start date
Jul 1, 2018
Status verified
Nov 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Tau positron emission tomography (PET)
    All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.

Primary Outcome Measure

measurement of longitudinal change in neuroimaging and the correlation between change on serial imaging measures and concurrent change on longitudinal measures of clinical performance in neurodegenerative AOS with or without non-fluent aphasia (NFA) [ Time Frame: approxiamtely 1-2 years after baseline imaging ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Sarah Boland, CCRP
[email protected]
507-284-3863

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies